IPHA
Innate Pharma S.A.
Price Chart
Latest Quote
$2.17
-0.06 (-2.69%)
Current Price
| Previous Close | $2.23 |
| Open | $2.21 |
| Day High | $2.29 |
| Day Low | $2.17 |
| Volume | 9,961 |
Stock Information
Note: Financial values converted from EUR to USD
| Shares Outstanding | 111.70M |
| Total Debt | $26.17M |
| Cash Equivalents | $39.78M |
| Revenue | $10.44M |
| Net Income | $-57.01M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $242.39M |
| EPS (TTM) | $-0.64 |
| Exchange | NMS |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $191.79M |
| Sales | $10.44M |
| Income | $-57.01M |
| Book/sh | $-0.27 |
| Cash/sh | $0.31 |
| Employees | 164 |
Financial Ratios
| Quick Ratio | 1.14 |
| Current Ratio | 1.27 |
Returns & Margins
| ROA | -38.85% |
| Operating Margin | -689.55% |
Ownership
| Insider Ownership | 1.40% |
| Institutional Ownership | 0.38% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -3.65 |
| P/S | 26.92 |
| P/B | -8.01 |
Analyst Data
| Recommendation | none |
| Target Price | $7.00 |
Technical Indicators
| SMA20 | $2.11 |
| SMA50 | $1.92 |
| SMA200 | $1.74 |
| RSI | 48.52 |
| ATR | 0.1870 |
| Shares Float | 70.57M |
| Short Float | 0.24% |
| Short Ratio | 0.67 |
| Volatility | 0.86 |
| Rel Volume | 0.02 |
Performance History
| Week | -3.98% |
| Month | +24.36% |
| Quarter | +18.58% |
| 6 Months | +26.53% |
| YTD | +19.23% |
| Year | +3.33% |
| 3 Years | -19.03% |
| 5 Years | -35.22% |
| 10 Years | -64.13% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-08-31 | $2.17 | 10,000 |
| 2026-08-27 | $2.23 | 6,100 |
| 2026-08-26 | $2.16 | 20,500 |
| 2026-08-25 | $2.27 | 28,000 |
| 2026-08-24 | $2.20 | 58,900 |
| 2026-08-21 | $2.26 | 44,400 |
| 2026-08-20 | $2.09 | 52,400 |
| 2026-08-19 | $2.12 | 27,100 |
| 2026-08-18 | $2.07 | 46,100 |
| 2026-08-17 | $2.26 | 217,200 |
| 2026-08-14 | $2.18 | 105,800 |
| 2026-08-13 | $2.54 | 198,700 |
| 2026-08-12 | $2.47 | 384,900 |
| 2026-08-11 | $2.15 | 446,100 |
| 2026-08-10 | $2.22 | 6,805,100 |
| 2026-08-07 | $1.73 | 5,000 |
| 2026-08-06 | $1.78 | 3,300 |
| 2026-08-05 | $1.77 | 1,800 |
| 2026-08-04 | $1.78 | 2,300 |
| 2026-08-03 | $1.72 | 47,300 |
About Innate Pharma S.A.
Innate Pharma S.A. operates as a biotechnology company that develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma; IPH4502, a novel and differentiated topoisomerase I inhibitor ADC conjugated to exatecan targeting Nectin-4; and Monalizumab, a dual checkpoint inhibitor that targets T Cells and NK Cells. It also develops IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway; IPH6401, an BCMA-targeting NK cell engager; IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager. In addition, the company develops IPH6501, a tetra-specific NK cell engager to activate receptors, NKp46 and CD16, tumor antigen (CD20) and an interleukin-2 receptor. The company has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech. Innate Pharma S.A. was incorporated in 1999 and is based in Marseille, France.
đ° Latest News
Innate Pharma SA (IPHA) (Q2 2026) Earnings Call Highlights: Strategic Partnerships and Pipeline ...
GuruFocus.com âĸ 2026-08-17T17:32:06ZSwedish Orphan Biovitrum (OM:SOBI) Following Its Lacutamab Deal And The Undervalued Narrative
Simply Wall St. âĸ 2026-08-15T02:08:02Z
Innate Pharma Secures âŦ30M, Extends Cash Runway Into 2028
MarketBeat âĸ 2026-08-14T19:02:31Z
Sobi licenses Innateâs CTCL drug for up to $580m as it heads to Phase III
Pharmaceutical Technology âĸ 2026-08-10T12:14:07Z
Innate Pharma Q1 Earnings Call Highlights
MarketBeat âĸ 2026-05-13T16:07:22Z
How Innate Pharma (ENXTPA:IPH) Story Is Shifting Around 2026 Catalysts And âŦ8 Target
Simply Wall St. âĸ 2026-03-27T06:06:39Z
Innate Pharma SA (IPHA) Full Year 2025 Earnings Call Highlights: Strategic Advances and ...
GuruFocus.com âĸ 2026-03-26T19:00:56ZInnate Pharma Q4 Earnings Call Highlights
MarketBeat âĸ 2026-03-26T15:08:16Z
Innate Pharma Receives US FDA Clearance to Begin Phase 3 Trial of Potential Skin Cancer Therapy
MT Newswires âĸ 2025-11-10T09:45:58ZInnate Pharma (IPHA) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?
Zacks âĸ 2025-11-06T14:55:02Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $3,238,438 | $14,665,350 | $60,307,924 | $57,610,968 |
| Operating Revenue | $2,656,286 | $14,600,279 | $60,295,142 | $58,327,910 |
| Expenses | ||||
| Interest Expense | $511,271 | $657,681 | $743,667 | $334,650 |
| Total Expenses | $65,317,220 | $74,595,630 | $75,029,049 | $76,696,490 |
| Other Income Expense | $3,914,711 | $269,579 | $2,976,993 | $-48,576,574 |
| Net Non Operating Interest Income Expense | $1,020,218 | $2,174,065 | $2,947,943 | $299,791 |
| Interest Expense Non Operating | $511,271 | $657,681 | $743,667 | $334,650 |
| Operating Expense | $65,317,220 | $74,595,630 | $75,029,049 | $76,696,490 |
| Other Operating Expenses | $1,851,034 | $330,002 | $-3,718,336 | $-152,219 |
| General And Administrative Expense | $12,780,618 | $13,865,907 | $13,650,941 | $16,817,337 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-57,142,690 | $-57,484,313 | $-8,796,189 | $-67,362,305 |
| Net Interest Income | $1,020,218 | $2,174,065 | $2,947,943 | $299,791 |
| Interest Income | $1,531,490 | $2,831,745 | $3,691,610 | $634,441 |
| Normalized Income | $-61,057,401 | $-57,753,892 | $-11,773,181 | $-18,785,731 |
| Net Income From Continuing And Discontinued Operation | $-57,142,690 | $-57,484,313 | $-8,796,189 | $-67,514,524 |
| Total Operating Income As Reported | $-62,756,216 | $-59,929,118 | $-14,721,125 | $-66,726,702 |
| Net Income Common Stockholders | $-57,142,690 | $-57,484,313 | $-8,796,189 | $-67,514,524 |
| Net Income | $-57,142,690 | $-57,484,313 | $-8,796,189 | $-67,514,524 |
| Net Income Including Noncontrolling Interests | $-57,142,690 | $-57,484,313 | $-8,796,189 | $-67,514,524 |
| Net Income Discontinuous Operations | $0 | $0 | $0 | $-152,219 |
| Net Income Continuous Operations | $-57,142,690 | $-57,484,313 | $-8,796,189 | $-67,362,305 |
| Pretax Income | $-57,142,690 | $-57,484,313 | $-8,796,189 | $-67,362,305 |
| Special Income Charges | $-677,434 | $0 | $0 | $-47,641,180 |
| Interest Income Non Operating | $1,531,490 | $2,831,745 | $3,691,610 | $634,441 |
| Operating Income | $-62,078,782 | $-59,930,280 | $-14,721,125 | $-19,085,522 |
| Per Share | ||||
| Diluted EPS | $-0.64 | $-0.71 | $-0.10 | $-0.85 |
| Basic EPS | $-0.64 | $-0.71 | $-0.10 | $-0.85 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-54,630,490 | $-54,779,223 | $-9,421,334 | $34,308,621 |
| Total Unusual Items | $3,914,711 | $269,579 | $2,976,993 | $-48,576,574 |
| Total Unusual Items Excluding Goodwill | $3,914,711 | $269,579 | $2,976,993 | $-48,576,574 |
| Reconciled Depreciation | $5,915,640 | $2,316,988 | $1,608,180 | $52,759,702 |
| EBITDA (Bullshit earnings) | $-50,715,779 | $-54,509,644 | $-6,444,341 | $-14,267,952 |
| EBIT | $-56,631,419 | $-56,826,632 | $-8,052,521 | $-67,027,654 |
| Diluted Average Shares | $104,102,950 | $94,180,803 | $97,735,429 | $92,540,087 |
| Basic Average Shares | $104,102,950 | $94,180,803 | $97,735,429 | $92,540,087 |
| Diluted NI Availto Com Stockholders | $-57,142,690 | $-57,484,313 | $-8,796,189 | $-67,514,524 |
| Tax Provision | $0 | $0 | $0 | $0 |
| Impairment Of Capital Assets | $0 | $0 | $0 | $47,641,180 |
| Restructuring And Mergern Acquisition | $677,434 | - | - | - |
| Gain On Sale Of Security | $4,592,145 | $269,579 | $2,976,993 | $-935,394 |
| Research And Development | $50,685,568 | $60,399,720 | $65,096,444 | $60,031,373 |
| Selling General And Administration | $12,780,618 | $13,865,907 | $13,650,941 | $16,817,337 |
| Other Gand A | $3,535,905 | $3,924,006 | $3,376,714 | $4,931,443 |
| Salaries And Wages | $9,244,713 | $9,941,901 | $10,274,227 | $11,885,893 |
Fetched: 2026-08-31
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $-25,219,614 | $10,264,931 | $59,824,540 | $61,117,824 |
| Total Assets | $72,878,224 | $129,048,337 | $203,563,790 | $231,576,804 |
| Total Non Current Assets | $18,602,138 | $29,417,848 | $31,576,806 | $69,097,141 |
| Other Non Current Assets | $1,100,395 | $668,138 | $101,092 | $176,621 |
| Non Current Accounts Receivable | $291,657 | $10,838,949 | $12,263,537 | $16,382,756 |
| Investmentin Financial Assets | $12,148,501 | $11,946,316 | $11,382,756 | $40,807,576 |
| Financial Assets Designatedas Fair Value Through Profitor Loss Total | $12,148,501 | $11,946,316 | $11,382,756 | $40,807,576 |
| Goodwill And Other Intangible Assets | $0 | $0 | $483,384 | $1,804,555 |
| Current Assets | $54,276,086 | $99,630,489 | $171,988,146 | $162,480,825 |
| Other Current Assets | $1,162 | - | $1,162 | $2,324 |
| Prepaid Assets | $5,564,722 | $3,868,231 | $10,535,673 | $8,510,342 |
| Receivables | $8,842,668 | $1,909,133 | $54,019,288 | $36,044,620 |
| Other Receivables | $135,952 | $103,416 | $120,846 | $70,881 |
| Taxes Receivable | $8,252,382 | $1,050,430 | $36,198,001 | $32,394,840 |
| Accounts Receivable | $454,334 | $755,287 | $17,700,441 | $3,578,898 |
| Cash Cash Equivalents And Short Term Investments | $39,867,534 | $93,853,125 | $107,432,023 | $117,923,540 |
| Cash And Cash Equivalents | $32,642,342 | $77,150,824 | $82,041,598 | $97,867,766 |
| Non Current Deferred Assets | - | - | $10,464,792 | $9,955,845 |
| Non Current Deferred Taxes Assets | - | - | $10,464,792 | $9,955,845 |
| Other Intangible Assets | - | - | $483,384 | $1,804,555 |
| Debt | ||||
| Total Debt | $26,229,375 | $36,015,570 | $46,354,868 | $49,094,817 |
| Long Term Debt And Capital Lease Obligation | $16,001,627 | $25,895,886 | $35,971,415 | $46,652,335 |
| Long Term Debt | $15,888,915 | $25,775,040 | $35,564,722 | $45,234,719 |
| Current Debt And Capital Lease Obligation | $10,227,748 | $10,119,684 | $10,383,453 | $2,442,482 |
| Current Debt | $9,894,260 | $9,804,787 | $9,819,893 | $1,485,010 |
| Other Current Borrowings | $9,894,260 | $9,804,787 | $9,819,893 | $1,485,010 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $98,097,838 | $118,783,406 | $143,255,866 | $168,654,425 |
| Total Non Current Liabilities Net Minority Interest | $55,512,433 | $80,458,981 | $97,199,627 | $120,620,496 |
| Other Non Current Liabilities | $36,890,541 | $47,789,913 | $52,325,121 | $61,570,996 |
| Non Current Deferred Liabilities | $0 | $3,282,594 | $5,366,024 | $9,204,044 |
| Current Liabilities | $42,585,405 | $38,324,424 | $46,056,239 | $48,033,929 |
| Other Current Liabilities | $7,554,032 | $8,648,617 | $8,884,499 | $11,878,922 |
| Current Deferred Liabilities | $3,282,594 | $715,780 | $6,815,013 | $7,622,589 |
| Payables And Accrued Expenses | $17,478,503 | $18,599,814 | $19,774,576 | $24,298,164 |
| Payables | $17,478,503 | $18,599,814 | $19,774,576 | $24,298,164 |
| Other Payable | $1,186,382 | $1,303,742 | $1,668,603 | $1,483,848 |
| Total Tax Payable | $7,606,321 | $8,089,705 | $8,158,262 | $6,946,316 |
| Accounts Payable | $8,685,800 | $9,206,368 | $9,947,711 | $15,867,999 |
| Non Current Deferred Taxes Liabilities | - | - | $10,464,792 | $9,955,845 |
| Equity | ||||
| Common Stock Equity | $-25,219,614 | $10,264,931 | $60,307,924 | $62,922,379 |
| Total Equity Gross Minority Interest | $-25,219,614 | $10,264,931 | $60,307,924 | $62,922,379 |
| Stockholders Equity | $-25,219,614 | $10,264,931 | $60,307,924 | $62,922,379 |
| Gains Losses Not Affecting Retained Earnings | $1,299,094 | $31,373 | $575,180 | $951,662 |
| Other Equity Adjustments | $1,299,094 | $31,373 | $575,180 | $951,662 |
| Retained Earnings | $-506,091,093 | $-448,947,241 | $-391,462,928 | $-383,820,586 |
| Other Equity Interest | - | - | - | - |
| Other | ||||
| Treasury Shares Number | $21,584 | $21,584 | $21,584 | - |
| Ordinary Shares Number | $108,878,395 | $97,387,590 | $93,936,773 | $92,426,942 |
| Share Issued | $108,899,979 | $97,409,174 | $93,958,357 | $92,426,942 |
| Tangible Book Value | $-25,219,614 | $10,264,931 | $59,824,540 | $61,117,824 |
| Invested Capital | $563,560 | $45,844,759 | $105,692,539 | $109,642,109 |
| Working Capital | $11,690,681 | $61,306,065 | $125,931,906 | $114,446,896 |
| Capital Lease Obligations | $446,200 | $435,742 | $970,253 | $2,375,087 |
| Total Capitalization | $-9,330,699 | $36,039,972 | $95,872,646 | $108,157,098 |
| Additional Paid In Capital | $474,126,185 | $454,309,778 | $446,496,625 | $441,130,601 |
| Capital Stock | $5,446,200 | $4,871,020 | $4,699,047 | $4,660,702 |
| Common Stock | $5,446,200 | $4,871,020 | $4,699,047 | $4,660,702 |
| Employee Benefits | $2,234,488 | $3,172,205 | $2,836,393 | $2,963,049 |
| Non Current Pension And Other Postretirement Benefit Plans | $2,234,488 | $3,172,205 | $2,836,393 | $2,963,049 |
| Non Current Deferred Revenue | $0 | $3,282,594 | $5,366,024 | $9,204,044 |
| Long Term Capital Lease Obligation | $112,712 | $120,846 | $406,693 | $1,417,616 |
| Long Term Provisions | $385,777 | $318,383 | $700,674 | $230,072 |
| Current Deferred Revenue | $3,282,594 | $715,780 | $6,815,013 | $7,622,589 |
| Current Capital Lease Obligation | $333,488 | $314,897 | $563,560 | $957,472 |
| Current Provisions | $4,042,528 | $240,530 | $198,699 | $1,791,773 |
| Investments And Advances | $12,148,501 | $11,946,316 | $11,382,756 | $40,807,576 |
| Net PPE | $5,061,585 | $5,964,443 | $7,346,038 | $9,925,633 |
| Gross PPE | $5,061,585 | $5,964,443 | $7,346,038 | $9,925,633 |
| Construction In Progress | $0 | $0 | $0 | $0 |
| Other Properties | $2,771,322 | $3,309,319 | $3,908,901 | $4,996,514 |
| Land And Improvements | $2,290,263 | $2,655,124 | $3,437,137 | $4,929,119 |
| Properties | $0 | $0 | $0 | $0 |
| Other Short Term Investments | $7,225,192 | $16,702,301 | $25,390,425 | $20,055,775 |
| Leases | - | $1,474,553 | $1,946,316 | - |
Fetched: 2026-08-31
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-40,564,722 | $-8,467,348 | $-61,462,932 | $-23,561,468 |
| Operating Activities | ||||
| Operating Cash Flow | $-37,832,907 | $-8,013,014 | $-61,300,255 | $-22,257,727 |
| Cash Flow From Continuing Operating Activities | $-37,832,907 | $-8,013,014 | $-61,300,255 | $-22,257,727 |
| Operating Gains Losses | $357,890 | $-628,631 | $671,624 | $-635,603 |
| Investing Activities | ||||
| Capital Expenditure | $-2,731,815 | $-454,334 | $-162,677 | $-1,303,742 |
| Investing Cash Flow | $23,971,647 | $10,690,216 | $8,469,672 | $2,181,036 |
| Cash Flow From Continuing Investing Activities | $23,971,647 | $10,689,054 | $8,468,510 | $2,181,036 |
| Net Other Investing Changes | $73,205 | $1,162 | $6,972 | $-1,162 |
| Financing Activities | ||||
| Financing Cash Flow | $-2,284,453 | $-6,981,176 | $7,053,219 | $-2,124,099 |
| Cash Flow From Continuing Financing Activities | $-2,284,453 | $-6,981,176 | $7,053,219 | $-2,124,099 |
| Cash Dividends Paid | - | - | $0 | $0 |
| Issuance Of Capital Stock | - | - | - | - |
| Net Other Financing Charges | - | - | - | - |
| Net Common Stock Issuance | - | - | - | - |
| Common Stock Issuance | - | - | - | - |
| Other | ||||
| Repayment Of Debt | $-2,743,435 | $-10,383,453 | $-10,354,404 | $-2,354,171 |
| End Cash Position | $82,041,598 | $77,150,824 | $32,642,342 | $97,867,766 |
| Beginning Cash Position | $97,867,766 | $82,041,598 | $77,150,824 | $120,562,397 |
| Effect Of Exchange Rate Changes | $318,383 | $-586,800 | $1,268,882 | $-497,327 |
| Changes In Cash | $-16,144,550 | $-4,303,974 | $-45,777,364 | $-22,197,304 |
| Proceeds From Stock Option Exercised | $458,982 | $3,402,277 | $17,407,622 | $230,072 |
| Net Issuance Payments Of Debt | $-2,743,435 | $-10,383,453 | $-10,354,404 | $-2,354,171 |
| Net Long Term Debt Issuance | $-2,743,435 | $-10,383,453 | $-10,354,404 | $-2,354,171 |
| Long Term Debt Payments | $-2,743,435 | $-10,383,453 | $-10,354,404 | $-2,354,171 |
| Interest Received Cfi | $0 | $0 | $450,848 | $0 |
| Net Investment Purchase And Sale | $26,455,961 | $11,143,388 | $8,174,529 | $3,485,940 |
| Sale Of Investment | $26,455,961 | $11,143,388 | $8,174,529 | $3,485,940 |
| Net Intangibles Purchase And Sale | $-2,323,960 | $0 | $0 | $-682,082 |
| Purchase Of Intangibles | $-2,323,960 | $0 | $0 | $-682,082 |
| Net PPE Purchase And Sale | $-233,558 | $-454,334 | $-162,677 | $-621,659 |
| Sale Of PPE | $174,297 | $0 | $0 | $0 |
| Purchase Of PPE | $-407,855 | $-454,334 | $-162,677 | $-621,659 |
| Change In Working Capital | $-37,290,262 | $45,505,461 | $-12,354,171 | $-14,528,236 |
| Other Non Cash Items | $6,972 | $-413,665 | $-411,341 | $154,543 |
| Stock Based Compensation | $4,945,387 | $4,582,849 | $2,982,803 | $4,937,253 |
| Unrealized Gain Loss On Investment Securities | $-1,849,872 | $-1,551,243 | $-524,053 | $1,594,237 |
| Provisionand Write Offof Assets | $-1,122,473 | $-340,460 | $3,869,393 | $974,901 |
| Depreciation Amortization Depletion | $5,915,640 | $2,316,988 | $1,608,180 | $52,759,702 |
| Depreciation And Amortization | $5,915,640 | $2,316,988 | $1,608,180 | $52,759,702 |
| Pension And Employee Benefit Expense | $331,164 | $376,482 | $-937,718 | $424,123 |
| Net Foreign Currency Exchange Gain Loss | $632,117 | $-1,028,352 | $1,582,617 | $-1,059,726 |
| Gain Loss On Sale Of PPE | $546,131 | $23,240 | $26,726 | $0 |
| Net Income From Continuing Operations | $-8,796,189 | $-57,484,313 | $-57,142,690 | $-67,514,524 |
| Issuance Of Debt | - | - | $0 | $0 |
| Interest Paid Cff | - | - | $0 | $0 |
| Long Term Debt Issuance | - | - | $0 | $0 |
| Purchase Of Investment | - | - | $0 | $0 |
| Change In Other Working Capital | - | - | - | $-27,227,515 |
| Change In Other Current Liabilities | - | - | - | $26,488,496 |
| Change In Payables And Accrued Expense | - | - | - | $-8,903,091 |
| Change In Payable | - | - | - | $-8,903,091 |
| Change In Account Payable | - | - | - | $-8,903,091 |
| Change In Receivables | - | - | - | $-4,884,964 |
| Changes In Account Receivables | - | - | - | $-4,884,964 |
| Gain Loss On Investment Securities | - | - | - | $-1,059,726 |
Fetched: 2026-08-31